We offer a selection of unique, high-quality assays for Cellular Allergy testing such as the BÜHLMANN Flow CAST® product group and numerous Allergens for Basophil Activation Testing and Neuroimmunology testing such as the BÜHLMANN GanglioCombi® products; the only screening ELISAs for anti-Ganglioside testing and Anti-MAG Autoantibodies ELISA. Other areas of BÜHLMANN’s focus include specialized niche products for Clinical Chemistry (ACE, GHB, etc.) as well as the first- to-market Chronobiology melatonin line of assays.
The BÜHLMANN fCAL® assay product line has a range of robust solutions that are validated and highly published worldwide. This portfolio services all types of users, from low volume to high throughput labs by offering a variety of test formats to best suit your needs. The BUHLMANN fCAL® product line is standardized against the ELISA, so no matter which assay you choose, results are reliable, accurate, and consistent across all the platforms.
BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing
Health Canada License: 80726 US: BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.
BÜHLMANN fCAL® turbo, the high throughput, random access fecal calprotectin assay – unique in speed, quality, flexibility
Health Canada License: 96808 US: BÜHLMANN fCAL® turbo is FDA 510(k) cleared. For in vitro Diagnostic Use.
Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!)
Health Canada Licenses: Quantum Blue® fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not for use in diagnostic procedures in the US
CALEX® Cap for rapid, clean, consistent and safe stool extraction
Health Canada License: 98839 US: Research Use Only. Not for use in diagnostic procedures in the US
The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.
This FDA 510k cleared, non-invasive, sensitive and specific assay is accurate, precise, efficient and offers reliable information to aid clinicians in selecting patients for further diagnostic procedures.
- Robust: accurate, precise & efficient assay to instill confidence
- Validated: in use worldwide providing over 1 million reliable patient results a year
- Published: highly referenced, >75 peer reviewed scientific articles
The BÜHLMANN fCAL® turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. The BÜHLMANN fCAL® turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.
This FDA 510k cleared, non-invasive, sensitive and specific assay is unique in speed, quality, and flexibility. This offers accurate results and reliable information to aid clinicians in selecting patients for further diagnostic procedures.
- Speed: fastest calprotectin test in the market, time-to-first-result within 10 minutes
- Quality: standardized against BÜHLMANN fCAL® ELISA, uses highly precise and reproducible PETIA technology
- Flexibility: can be applied on most open chemistry platforms streamlining your workflow using random access automation
Vice President, Business Development
Collin joined BDC in 2015 as the VP of Business Development. He has a MS in Cell Physiology, has been studying biomarkers in the medical diagnostics industry for 10+ years and has worked and published in the area of Diabetes, IBD, Cystic Fibrosis and neural pathobiology.
Technical Sales Specialist
Jennifer joined BDC as a Technical Sales Specialist in 2016, having spent 17 years performing Clinical Microbiology and Molecular Diagnostics in various hospital laboratory settings including MA General Hospital and Southern New Hampshire Medical Center. She is ASCP certified and received her BS in Medical Technology at the University of New Hampshire.